Regulation & Policy
MHRA extends Casgevy approval to children aged five and over with sickle cell disease and β-thalassaemia
The MHRA has lowered the minimum age for the gene-editing treatment Casgevy in severe sickle cell disease and transfusion-dependent β-thalassaemia from 12 to five.

The Medicines and Healthcare products Regulatory Agency (MHRA) has extended the UK authorisation of Casgevy (exagamglogene autotemcel) to children aged five and over with severe sickle cell disease and transfusion-dependent β-thalassaemia. The agency announced the decision on 30 October 2026.
The gene-editing treatment was previously authorised in the UK for patients aged 12 and over with these conditions. The extension applies to younger children who meet the eligibility criteria. According to the MHRA, the marketing authorisation extension was granted on 29 October 2026 to Vertex Pharmaceuticals (Europe) Ltd.
How the treatment works
Both conditions are genetic and are caused by errors in the genes for haemoglobin, which red blood cells use to carry oxygen around the body. The MHRA said severe sickle cell disease can lead to attacks of very severe pain, serious and life-threatening infections, and anaemia. In β-thalassaemia, the genetic error can lead to severe anaemia. The agency said patients often need a blood transfusion every three to five weeks, as well as injections and medicines throughout their lives.
Casgevy edits a faulty gene in a patient's bone marrow stem cells so that the body produces functioning haemoglobin. The stem cells are collected from the patient, edited in a laboratory and infused back after conditioning treatment, which prepares the bone marrow for the modified cells. After the infusion, patients may need to stay in hospital while the treated cells establish themselves in the bone marrow and begin producing red blood cells with functioning haemoglobin.
The MHRA listed nausea, fatigue, fever and increased risk of infection as side effects associated with the treatment.
Julian Beach, MHRA Executive Director Operations, said the approval rests on a careful assessment of the available evidence on the treatment's safety, quality and effectiveness. He added: "As with all medicines, we will continue to closely monitor the safety and effectiveness of Casgevy."
The MHRA said approximately 15,000 people in the UK have sickle cell disorder. It said the Summary of Product Characteristics and Patient Information leaflets will be published on the MHRA Products website within seven days of approval.
Why it matters
The decision widens the age range in which Casgevy can be used in the UK, which could enlarge the pool of patients that Vertex and specialist treatment centres plan for. The process involves stem cell collection, conditioning treatment and a possible hospital stay, so demand for younger patients could affect capacity at the centres that deliver it. The MHRA announcement does not address NHS funding or access, so commercial teams would need to look to other sources on that.
Source: MHRA
Related stories


